Clean Tech Firm Making Important PFAS Breakthrough - The Streetwise Reports

BioLargo Inc.'s CEO Dennis P. Calvert shared a comprehensive mid-year update highlighting the clean technology company's progress across multiple subsidiaries and breakthrough innovations.

The company is approaching commercialization inflection points across its diverse portfolio of environmental and medical technologies. BioLargo's family of companies includes subsidiaries focused on water treatment, medical devices, battery technology, and environmental engineering services. Key developments include their PFAS removal technology gaining regulatory validation, medical subsidiary Clyra securing major distribution agreements, and breakthrough battery technology attracting global joint venture interest.

• PFAS Treatment Leadership: The company's AEC technology effectively removes "forever chemicals" to below 4 parts per trillion, exceeding EPA standards and attracting Fortune 500 clients for wastewater treatment projects
• Medical Innovation Expansion: Clyra Medical launched FDA-cleared wound care products through established distributors, gaining access to over 14,600 medical facilities across the United States
• Revolutionary Battery Technology: Cellinity technology is attracting international joint venture partners with four MOUs signed for factories projected to generate $500 million annual revenue each
• Strong Engineering Growth: BioLargo Engineering demonstrated 152% revenue growth in Q1 2025, driven by environmental services contracts including U.S. Air Force base partnerships